Your browser is no longer supported. Please, upgrade your browser.
Settings
APRI Apricus Biosciences, Inc. daily Stock Chart
APRI [NASD]
Apricus Biosciences, Inc.
Index- P/E- EPS (ttm)-0.71 Insider Own0.50% Shs Outstand23.34M Perf Week-15.12%
Market Cap6.54M Forward P/E- EPS next Y-0.62 Insider Trans0.00% Shs Float22.74M Perf Month-1.72%
Income-11.10M PEG- EPS next Q-0.14 Inst Own10.50% Short Float5.00% Perf Quarter-42.19%
Sales- P/S- EPS this Y15.90% Inst Trans-62.14% Short Ratio1.84 Perf Half Y-60.49%
Book/sh0.23 P/B1.22 EPS next Y-8.80% ROA-150.50% Target Price1.25 Perf Year-84.18%
Cash/sh0.29 P/C0.96 EPS next 5Y- ROE-213.70% 52W Range0.25 - 3.34 Perf YTD-84.78%
Dividend- P/FCF- EPS past 5Y36.20% ROI- 52W High-91.62% Beta1.24
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low12.04% ATR0.03
Employees11 Current Ratio3.70 Sales Q/Q- Oper. Margin- RSI (14)43.15 Volatility10.44% 11.42%
OptionableNo Debt/Eq0.00 EPS Q/Q36.50% Profit Margin- Rel Volume0.47 Prev Close0.28
ShortableYes LT Debt/Eq0.00 EarningsAug 15 AMC Payout- Avg Volume619.29K Price0.28
Recom2.50 SMA20-5.00% SMA50-12.29% SMA200-68.29% Volume293,125 Change-1.27%
Feb-16-18Downgrade H.C. Wainwright Buy → Neutral $1
Apr-26-17Initiated Rodman & Renshaw Buy $4
Nov-06-15Reiterated FBR Capital Outperform $22 → $19
Nov-06-15Downgrade ROTH Capital Buy → Neutral $1.50
Jul-23-12Initiated Ascendiant Capital Markets Strong Buy $6
Jun-14-12Initiated JMP Securities Mkt Outperform $6
Dec-14-10Initiated Dawson James Buy $5.50
Aug-09-18 06:18PM  Apricus: 2Q Earnings Snapshot Associated Press
04:05PM  Apricus Biosciences Provides Corporate Update and Second Quarter 2018 Financial Results GlobeNewswire
Jul-30-18 08:00AM  Apricus Biosciences, Inc. Announces Merger Agreement with Seelos Therapeutics, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders GlobeNewswire
Jul-02-18 07:05AM  Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks ACCESSWIRE
Jun-04-18 02:02PM  What Does Apricus Biosciences Incs (NASDAQ:APRI) Share Price Indicate? Simply Wall St. -6.96%
07:30AM  Complimentary Technical Snapshots on Axovant Sciences and Three More Biotech Stocks ACCESSWIRE
May-24-18 05:23PM  With A -24.18% Earnings Drop, Is Apricus Biosciences Incs (NASDAQ:APRI) A Concern? Simply Wall St.
May-03-18 05:40PM  Apricus: 1Q Earnings Snapshot Associated Press
04:02PM  Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results: GlobeNewswire
04:01PM  Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results GlobeNewswire
Apr-16-18 08:41AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga -35.38%
08:25AM  Apricus mulls options; to sell U.S. rights to Vitaros Reuters
07:06AM  FDA asks for new formulation of Apricus' erectile dysfunction cream Reuters
07:01AM  Apricus Biosciences Announces Outcome of Vitaros(TM) End-of-Review Meeting with FDA GlobeNewswire
07:00AM  Apricus Biosciences Announces Outcome of Vitaros End-of-Review Meeting with FDA GlobeNewswire
Apr-04-18 04:01PM  Apricus Biosciences Announces Closing of $3.55 Million Public Offering GlobeNewswire
Mar-29-18 06:31AM  Edge Therapeutics And Apricus Biosciences Are Moving: Heres Why Market Exclusive
Mar-28-18 08:01AM  Apricus Biosciences Announces Pricing of $3.55 Million Public Offering GlobeNewswire -33.62%
Mar-27-18 04:40PM  Apricus Biosciences Announces Proposed Public Offering GlobeNewswire -11.75%
Mar-26-18 03:26PM  Apricus Biosciences Announces Scheduling of Vitaros(TM) End-of-Review Meeting with FDA GlobeNewswire
07:00AM  Apricus Biosciences Announces Scheduling of Vitaros End-of-Review Meeting with FDA GlobeNewswire
Mar-22-18 08:05AM  Apricus Biosciences, Vitaros Update, The ED Market, Analysts Target Price, Pipeline ACCESSWIRE
07:30AM  Blog Exposure - Cipher to Acquire Cardiomes Canadian Business Portfolio for $25.5 Million in Cash ACCESSWIRE
Mar-06-18 08:01AM  Edited Transcript of APRI earnings conference call or presentation 1-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-01-18 05:09PM  Apricus reports 4Q loss Associated Press -5.32%
04:02PM  Apricus Biosciences, Inc. : Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
04:01PM  Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
12:00PM  Apricus Biosciences, Inc. to Host Earnings Call ACCESSWIRE
11:15AM  At $0.9401, Is Apricus Biosciences Inc (NASDAQ:APRI) A Buy? Simply Wall St.
Feb-28-18 10:08AM  Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Benzinga
Feb-21-18 08:50AM  Apricus Biosciences (APRI) Soars: Stock Adds 8.6% in Session Zacks
07:01AM  Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call GlobeNewswire
07:00AM  Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call GlobeNewswire
Feb-20-18 10:41AM  Heres Whats Moving Apricus Biosciences And Pacira Pharmaceuticals Market Exclusive +8.65%
09:39AM  What's Next For Apricus Biosciences' Vitaros? Benzinga
Feb-19-18 02:00AM  Interested In Apricus Biosciences Inc (NASDAQ:APRI)? Heres What Its Recent Performance Looks Like Simply Wall St.
Feb-16-18 12:20PM  Is It Game Over After Apricus Biosciences Inc (APRI) FDA Rejection? SmarterAnalyst -67.40%
11:23AM  There's No Place Like Home in Biotech The Wall Street Journal
08:59AM  Shares of Apricus tank after FDA declines to OK erectile dysfunction cream Reuters
08:52AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:07AM  U.S. FDA declines to approve Apricus' erectile dysfunction cream Reuters
07:01AM  Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros(TM) GlobeNewswire
07:00AM  Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros GlobeNewswire
Nov-21-17 01:39PM  Should You Buy Apricus Biosciences Inc (APRI) Now? Simply Wall St.
Nov-07-17 09:24PM  Edited Transcript of APRI earnings conference call or presentation 2-Nov-17 8:30pm GMT Thomson Reuters StreetEvents
09:00AM  SeeThruEquity Issues Update Note on Apricus Biosciences, Inc. (Nasdaq CM: APRI) with Target Price of $4.30 ACCESSWIRE
Nov-02-17 05:32PM  Apricus reports 3Q loss Associated Press
04:01PM  Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results GlobeNewswire
Oct-26-17 07:02AM  Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call GlobeNewswire
07:00AM  Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call GlobeNewswire
Oct-10-17 07:59PM  Should You Be Concerned About Apricus Biosciences Incs (APRI) Risks? Simply Wall St.
07:02AM  Apricus Biosciences to Present at the 2017 BIO Investor Forum GlobeNewswire
Oct-03-17 09:00AM  SeeThruEquity Issues Company Update on Apricus Biosciences (NASDAQ:APRI) with Target Price of $4.30 ACCESSWIRE
Sep-11-17 07:00AM  Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market GlobeNewswire
Sep-06-17 08:31AM  Apricus, Topical Formulations Leading the Way, Q2 Review, and Outlook ACCESSWIRE
Sep-05-17 07:01AM  Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire
Aug-31-17 07:00AM  Apricus Biosciences Announces FDA Acknowledgement of Vitaros Class 2 NDA Resubmission GlobeNewswire
Aug-29-17 07:00AM  Apricus Biosciences Files NDA Resubmission for Vitaros GlobeNewswire
Aug-23-17 06:01PM  Edited Transcript of APRI earnings conference call or presentation 2-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-11-17 04:56PM  ETFs with exposure to Apricus Biosciences, Inc. : August 11, 2017 Capital Cube
Aug-02-17 10:55PM  Apricus reports 2Q loss Associated Press -6.99%
04:02PM  Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results GlobeNewswire
04:01PM  Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results GlobeNewswire
10:00AM  Investor Network: APRICUS BIOSCIENCES, INC. to Host Earnings Call ACCESSWIRE
Jul-26-17 07:01AM  Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call GlobeNewswire +12.50%
May-19-17 04:56AM  Edited Transcript of APRI earnings conference call or presentation 11-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-11-17 07:10PM  Edited Transcript of APRI earnings conference call or presentation 11-May-17 8:30pm GMT Thomson Reuters StreetEvents +7.63%
05:50PM  Apricus posts 1Q profit Associated Press
04:02PM  Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results GlobeNewswire
03:25PM  Investor Network: APRICUS BIOSCIENCES, INC. to Host Earnings Call Accesswire
May-04-17 07:01AM  Apricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study GlobeNewswire
06:46AM  Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call GlobeNewswire
May-02-17 04:06PM  Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements GlobeNewswire -10.62%
Apr-21-17 06:01AM  Apricus Biosciences Announces Pricing of $7.0 Million Public Offering GlobeNewswire -12.41%
Apr-19-17 02:09PM  ETFs with exposure to Apricus Biosciences, Inc. : April 19, 2017 Capital Cube
Apr-13-17 07:30AM  Apricus Biosciences and Protalix Biotherapeutics Seeing Opposite Sides of FDA Clinical Trials Accesswire -11.82%
Apr-07-17 03:49PM  ETFs with exposure to Apricus Biosciences, Inc. : April 7, 2017 Capital Cube -6.08%
Mar-27-17 03:48PM  ETFs with exposure to Apricus Biosciences, Inc. : March 27, 2017 Capital Cube
03:48PM  ETFs with exposure to Apricus Biosciences, Inc. : March 27, 2017
Mar-20-17 09:03AM  Apricus Biosciences, Inc. :APRI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
09:03AM  Apricus Biosciences, Inc. :APRI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
Mar-17-17 01:04PM  APRICUS BIOSCIENCES, INC. Financials
Mar-13-17 05:22PM  Apricus reports 4Q loss Associated Press +7.20%
04:30PM  Apricus Biosciences Inc Earnings Call scheduled for 4:30 pm ET today
04:20PM  Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
04:19PM  APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:13PM  Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 Apricus Biosciences Inc Earnings Release - 4:01 pm ET
Mar-09-17 01:32PM  Apricus Biosciences Sells ED Therapy Rights Investopedia
01:32PM  Apricus Biosciences Sells ED Therapy Rights at Investopedia
07:02AM  Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call GlobeNewswire
07:00AM  Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call GlobeNewswire
Mar-08-17 04:04PM  APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material D
04:02PM  Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals GlobeNewswire
04:01PM  Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals GlobeNewswire
Feb-09-17 06:06AM  APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events
06:02AM  Apricus Biosciences Receives Positive Nasdaq Listing Determination GlobeNewswire
06:00AM  Apricus Biosciences Receives Positive Nasdaq Listing Determination GlobeNewswire
Feb-08-17 07:01AM  Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference GlobeNewswire
07:00AM  Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference GlobeNewswire
Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma. It has a license and stock issuance agreement with Forendo Pharma Ltd. to develop and commercialize fispemifene, a tissue-specific selective estrogen receptor modulator to treat symptomatic secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. Apricus Biosciences, Inc. operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.